RxDoctor Payments Data

Mina Tanaka, MD

Internal Medicine · Shiprock, NMNPI 1740661248

Payments from drug & device makers

$869in general payments, 2019–2025

Across 27 payments — averaging $32.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$335
  • AstraZeneca$186
  • Indivior Inc.$164
  • AbbVie$134
  • Viiv Healthcare Company$23
  • Merck$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$869100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$869 in reported general payments places this provider in the 85th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$29,545
Medicare patients
158
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$39,405
OzempicSemaglutide31$30,053
EliquisApixaban25$22,160
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,471
SynthroidLevothyroxine Sodium15$1,514
Atorvastatin Calcium46$1,031
Gabapentin24$442
Metformin Hcl ErMetformin Hcl30$351
Amitriptyline Hcl15$266
Lisinopril54$244
Tamsulosin Hcl12$186
Diclofenac Sodium18$132
Simvastatin17$131
Metformin Hcl19$127
Losartan Potassium14$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$134$1,51415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Shiprock

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →